Notice: Fall 2017 exams affected by natural disasters... More >

Expand/Collapse Close

ABIM knows that we have many physicians whose lives have been upended by recent natural disasters. If you live or work near an affected area, we understand that the weather may have impacted your ability to take your Fall 2017 exam as scheduled. We have developed a series of options to help you get through this process as smoothly as possible. If you have any questions, please call us at 1-800-441-ABIM (2246) or email request@abim.org.

American Board of Internal Medicine home page

MOC is a professionally determined standard that attests that an internist is staying current in knowledge and practice throughout his/her career.

Initial Certification indicates that physicians have met rigorous standards through intensive study, accredited training and evaluation and that they have the clinical judgment, skills and attitudes essential for the delivery of excellent patient care.

For more than 75 years, Certification by ABIM has stood for the highest standard in internal medicine and its 20 subspecialties.

Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee

Susan C. Brozena, MD, Chair

Dr. Brozena is an Associate Professor of Medicine at the University of Pennsylvania School of Medicine and the Medical Director of Cardiology of the Ambulatory Center at Penn Medicine Radnor and a member of the Heart Failure Transplant Program. She is board certified in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology.

Previously, Dr. Brozena was the Associate Director for Ambulatory Care at the Hospital of the University of Pennsylvania Heart Failure/Transplant program. Prior to that, she was the Medical Director of the Heart Failure and Transplant Program at Temple University Hospital, then Hahnemann University Hospital in Philadelphia.

Dr. Brozena is currently the Chair of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee. She had previously been a member of that committee. She is also an elected member of the Academy of Master Clinicians of the University of Pennsylvania School of Medicine.

Dr. Brozena received a degree in nursing from Wilkes University and her medical degree from Temple University School of Medicine. She completed her medical internship, residency and cardiology fellowship at Temple University Hospital.

As of January 2017, Dr. Brozena reported no external relationships.

Biykem Bozkurt, MD, PhD

Dr. Bozkurt, who is board certified in Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology, is the Medical Care Line Executive (Medicine Department Chair) and Cardiology Chief at the DeBakey VA Medical Center; W.A. “Tex” and Deborah Moncrief, Jr., Chair; Mary and Gordon Cain Chair and Professor of Medicine; and Vice-Chair of Department of Medicine at Baylor College of Medicine; Director of the Winters Center for Heart Failure and Associate Director of Cardiovascular Research Institute at Baylor College of Medicine in Houston, Texas. She teaches medical students, residents and fellows and mentors trainees in clinical and translational research.

Previously, Dr. Bozkurt served as the Associate Director of Cardiovascular Research Institute at Baylor College of Medicine and Assistant to Chief of Medicine at the DeBakey VA Medical Center.

Throughout her academic career, Dr. Bozkurt has received numerous awards or recognition including the Fulbright & Jaworski L.L.P. Faculty Excellence Awards in 2003, 2004, 2007 and 2012; Baylor College of Medicine Barbara and Corbin J. Robertson, Jr. Presidential Award for Excellence in Education in 2014 and Master Clinician Lifetime Award at Baylor College of Medicine in 2014. Dr. Bozkurt was awarded the very prestigious National American College of Cardiology Proctor Harvey M.D. Young Teacher Award in 2005.

Dr. Bozkurt currently serves on the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee; the American College of Cardiology and American Heart Association Task Force on Clinical Data Standards; the American College of Cardiology and American Heart Association Task Force for Practice Guidelines; the Heart Failure Society of America Executive Council; and the American College of Cardiology Heart Failure Council. She actively participates in clinical research and national and international scientific sessions in the field of heart failure.

Dr. Bozkurt received her medical degree from University of Istanbul. She completed internal medicine residency, chief medical residency and cardiology fellowship at Baylor College of Medicine and subspecialty fellowship training in heart failure and cardiac transplantation at the University Pittsburgh Medical Center. She received her doctoral degree as a National Institutes of Health K30 scholar in clinical translational science in heart failure.

As of January 2017, Dr. Bozkurt reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Baylor College of Medicine, from the following companies:

  • Novartis, for a study of serelaxin added to standard therapy in acute heart failure (Relax-II) and for a study of sacubitril/valsartan vs. enalapril in patients stabilized after acute heart failure (Pioneer).
  • Circulation: Heart Failure, receiving compensation for service as Associate Editor.

Dr. Bozkurt serves in significant roles with the following organization(s), receiving reimbursement or compensation as listed:

  • American College of Cardiology, Chair-Elect of ACC Heart Failure Council; receiving reimbursement for travel expenses.
  • American College of Cardiology Foundation/American Heart Association, Member of ACCF/AHA Task Force for Practice Guidelines; Chair-Elect for ACCF/AHA Task Force for Data Standards, receiving reimbursement for travel expenses.
  • Heart Failure Society of America, Member of Executive Council, receiving reimbursement for travel expenses.

Maria Rosa Costanzo, MD

Dr. Costanzo, who is board certified in Advanced Heart Failure and Transplant Cardiology, is currently the Medical Director of the Midwest Heart Specialists – Advocate Medical Group Heart Failure and Pulmonary Arterial Hypertension Programs, and Medical Director of the Edward Hospital Center for Advanced Heart Failure.

Previously, she directed the Loyola University Chicago Heart Failure and Cardiac Transplant Program from 1988 to 1994 and the Rush Heart Failure and Cardiac Transplant Program from 1994 to 2001. From 1995 to 2002, Dr. Costanzo was the John H. and Margaret V. Krehbiel Professor of Cardiology at Rush Medical College, Chicago. In 2002, she was appointed by the U.S. Secretary of Health and Human Services, The Honorable Tommy Thompson, to a four-year term on the National Heart and Blood Institute Advisory Council.

Dr. Costanzo has published more than 160 peer-reviewed manuscripts and is the author of numerous review papers, monographs and book chapters. From 1995 to 2000, she was the Editor in Chief of The Journal of Heart and Lung Transplantation. She was the Principal Investigator for the Multicenter, Prospective Randomized Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) Trial published in the Journal of the American College of Cardiology in February 2007.

Dr. Costanzo is currently a member of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee. She is also a member of the American Heart Association, American College of Cardiology, the International Society of Heart and Lung Transplant (ISHLT), the Heart Failure Society of America and the American College of Physicians. She is currently chairing the preparation of the ISHLT Guidelines for the Care of Heart Transplant Recipients. She is a member of special panels convened by the National Institutes of Health to review large grants in the areas of heart failure and mechanical circulatory support.

Dr. Costanzo graduated summa cum laude from the University of Bologna Medical School, Italy, and completed a fellowship in cardiovascular disease at Loyola University Chicago.

As of January 2017, Dr. Costanzo reported the following external relationships:

Funding for clinical trial expenses, paid to Advocate Medical Group-Midwest Heart Specialists, from the following companies:

  • CardioKinetix, to evaluate a structural heart medical device in patients with ischemic heart failure (PARACHUTE trial).
  • Respicardia, to evaluate an implantable stimulation device for the treatment of central sleep apnea (remedē® System pivotal trial).
  • St. Jude, to evaluate the effect of an implanted left atrial pressure sensor in heart failure (LAPTOP trial).

Attendance at investigators' meetings, with compensation as listed from the following companies:

  • Respicardia, for meetings related to the remedē® System pivotal trial, receiving reimbursement for travel expenses.

Service on data and safety monitoring boards for the following companies, with compensation as listed:

  • Medtronic, for oversight of the DeLIvery clinical trial, receiving honoraria.

Post-marketing clinical research, from the following company, with compensation as listed:

  • St. Jude, for service on the steering committee of the CardioMEMS post-market trial, receiving honoraria.

Stephen S. Gottlieb, MD

Dr. Gottlieb, board certified in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology, is Professor of Medicine at the University of Maryland School of Medicine. Dr. Gottlieb has pursued clinical research in heart failure (HF) throughout his career, focusing on the physiology and therapy of the disease, with a particular interest in neurohormonal activation and renal function in HF patients. He has studied the impact of adenosine antagonists and other medications and interventions on renal function and the physiology of renal function in heart failure patients.

Currently, Dr. Gottlieb is a member of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee. He has been Chair of the Education Committee and a member of other committees of the Heart Failure Society of America. He has also served on the Board of the Maryland chapter of the American College of Cardiology. Dr. Gottlieb was the Principal Investigator in the United States of the groundbreaking MERIT-HF evaluation of beta blockers. He has published about the interaction of depression and HF, and investigated the effects of home telemonitoring, sleep abnormalities and genetic polymorphisms in HF patients. He is also an Associate Editor of the Journal of Cardiac Failure and Guest Associate Editor of the Journal of the American College of Cardiology – Heart Failure (JACC-HF).

Dr. Gottlieb received his medical degree from Brown University School of Medicine and trained in internal medicine at the University of Chicago and in cardiology at Mt. Sinai in New York.

As of January 2017, Dr. Gottlieb reported the following external relationships:

Funding for clinical trial expenses, staff and salary support, paid to the University of Maryland, from the following companies:

  • Alnylam, to evaluate the treatment of amyloidosis.
  • Bristol-Myers Squibb, to evaluate the effect of dapaglifozin in congestive heart failure.
  • Novartis, to evaluate the treatment of heart failure with seralaxin.
  • Pfizer, to evaluate the treatment of cardiac amyloidosis with tafamidis.
  • Respircardia, for a study of treatment of central sleep apnea.

Attendance at investigators’ meetings, with compensation for travel expenses from the following company:

  • Alnylam, for a study of treatment of amyloidosis.

Service on a research-related expert panel or advisory board for the following company, with compensation as listed:

  • Serenity, for discussion of vasopressin antagonist for nocturia, receiving reimbursement for travel expenses and honoraria.

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following company, with compensation for travel expenses and/or honoraria:

  • Bristol-Myers Squibb, concerning HNO treatment of acute decompensated heart failure.

Work as an author or editor for following company, with compensation as listed:

  • UpToDate, receiving compensation as an editor.
  • Journal of Cardiac Failure, receiving compensation as an editor.

Maryl R. Johnson, MD

Dr. Johnson is Professor of Medicine and a Heart Failure/Transplant Cardiologist at the University of Wisconsin School of Medicine and Public Health. She is board certified in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure and Transplant Cardiology.

Prior to coming to the University of Wisconsin in 2002 as the Medical Director of Heart Failure and Transplantation, Dr. Johnson served as the Medical Director of Heart Failure and Transplantation at Northwestern Memorial Hospital, as Associate Medical Director of Heart Failure and Transplantation at Rush Presbyterian St. Luke’s Medical Center and Loyola University Medical Center, and as the Medical Director of Heart Transplantation at the University of Iowa.

Dr. Johnson is a member of the American Board of Internal Medicine Cardiology Board Advanced Heart Failure & Transplant Cardiology Exam Committee. She served as a resident member of the National Heart, Lung, and Blood Institute Advisory Council and has been a member and chair of NIH review committees. She is past-President of the American Society of Transplantation and has served as Chair of the Heart Failure and Transplant Committee of the American College of Cardiology. She a past Chair of the UNOS/OPTN Thoracic Organ Committee, past Secretary of the UNOS/OPTN Board of Directors, and current Chair of the UNOS/OPTN Data Advisory Committee. She is currently the Past President of the International Society for Heart and Lung Transplantation and is Past Chair of the society’s Standards and Guidelines Committee. She serves on the editorial board of The Journal of Heart and Lung Transplantation.

Dr. Johnson earned a bachelor’s degree in zoology at Iowa State University and her medical degree from the University of Iowa School of Medicine. She trained in internal medicine and cardiovascular medicine at the University of Iowa, where she also served as Chief Medical Resident.

As of July 2017, Dr. Johnson reported the following external relationships:

Consulting on design of new drugs or devices, clinical trials, the use of specific agents or other research-related activities for the following companies, with compensation for travel expenses:

  • GE Medical, serving as a member of the steering committee for the ADMIRE clinical trial, evaluating the use of AdreView imaging to determine the need for an implantable cardiac defibrillator in patients with left ventricular ejections fraction of 30-35%.

Dr. Johnson serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • International Society for Heart & Lung Transplantation, Past President, receiving travel reimbursement.
  • United Network for Organ Sharing, Chair of the Data Advisory Board, receiving travel reimbursement.

Andrew Kao, MD

Dr. Kao is currently an Associate Professor of Medicine at the University of Missouri-Kansas City and Medical Director of the Heart Transplant Program at St. Luke’s Hospital Mid America Heart Institute. He is also Medical Director of the Cardiopulmonary Exercise Laboratory. He was previously an Assistant Professor of Medicine at the University of Pennsylvania in the Division of Cardiology, Section of Heart Failure and Transplant. Prior to that, he was an Assistant Professor of Medicine at the Oregon Health Sciences University, Division of Cardiology, Section of Heart Failure and Transplant. He is board certified in Cardiovascular Disease and in Advanced Heart Failure and Transplant Cardiology.

Dr. Kao has been actively involved in all aspects of heart failure and transplant clinical research, and was on the Steering Committee of the HF-ACTION study and will be on the Steering Committee of the PARACHUTE-HF study. He was one of the co-chairs of an International Society of Heart and Lung Transplant (ISHLT) Academy Core Competency Course for Heart Failure and Cardiac Transplant Medicine in 2016. Dr. Kao is a member of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure & Transplant Cardiology Exam Committee. He has been an abstract reviewer for the American College of Cardiology, ISHLT and American Heart Association. He has given numerous lectures on heart failure and transplant regionally and nationally, and has also served on several United Network of Organ Sharing committees.

Dr. Kao graduated summa cum laude with a bachelor’s degree from Carleton College in Northfield, Minnesota, and his medical degree from the University of Chicago Pritzker School of Medicine. He completed internal medicine residency at the University of Minnesota and a cardiovascular fellowship at Duke University, and training in heart failure and transplant cardiology at Oregon Health Sciences University.

As of July 2017, Dr. Kao reported the following external relationships:

Funding for clinical trial expenses and staff, paid to St. Luke’s Cardiovascular Consultants, from the following companies:

  • CardioKinetix, for a randomized trial of the Parachute device for ventricular apical akinesis or aneurysm in heart failure.
  • CareDx, D-OAR, registry of clinical use of gene expression profiling post-heart transplant to correlate with outcomes, with blood samples for donor-derived cell-free DNA in detecting rejection.
  • Respircardia, to investigate the use of a phrenic nerve stimulator system to treat central sleep apnea.
  • Sensible Medical, a randomized trial of the utility of a wearable vest with radar technology to detect lung fluid, to see if such monitoring in heart failure patients may reduce hospitalizations for heart failure.

Hector O. Ventura

Dr. Ventura, who is board certified in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology, is the Section Head, Cardiomyopathy and Heart Transplant Center at the Ochsner Clinic Foundation, New Orleans, Louisiana. He is also a Professor, Cardiology, The University of Queensland School of Medicine, Ochsner Clinical School, Brisbane, Australia as well as a Professor of Medicine at the Tulane University School of Medicine in New Orleans.

From 1997 to 2000, Dr. Ventura served as Clinical Professor of Medicine, Director of Cardiovascular Research and Co-Director of Advanced Heart Failure/Cardiac Transplantation at the Tulane University Medical Center in New Orleans. Prior to that, he served as co-Director of the Advanced Heart Failure and Heart Transplant Program at Ochsner Medical Institutions.

Dr. Ventura's research includes studies on arterial hypertension following cardiac transplantation, the effect of digitalis on mortality in heart failure, and lipid profiles after cardiac transplantation. He has co-authored more than 550 articles, abstracts and book chapters and is on the editorial boards of numerous peer-reviewed journals, including the Journal of Heart and Lung Transplantation and the Journal of the American College of Cardiology.

He is a fellow of the American College of Cardiology and serves as a member of the Cardiology Training & Workforce Committee. Dr. Ventura is a past Governor of the Louisiana Chapter of the American College of Cardiology, and a member of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee. He is also a member of other professional societies, including the American Heart Association, American Society of Transplant Physicians, International Society of Heart Transplantation and American Osler Society.

After graduating from the National University of Buenos Aires School of Medicine in Argentina, Dr. Ventura completed an internship and residency at the Central Military Hospital in Buenos Aires, followed by research fellowships in arterial hypertension and cardiovascular diseases, an internship and an internal medicine residency at the Ochsner Medical Institutions in New Orleans.

As of January 2017, Dr. Ventura reported the following external relationships:

Funding for clinical trial expenses, paid to Newark Beth Israel Medical Center, from the following company:

  • Pfizer, to evaluate tafamidis for the treatment of cardiac amyloidosis.

Dr. Ventura serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, President of Louisiana Chapter, receiving reimbursement for travel expenses.

Mark J. Zucker, MD

Dr. Zucker, board certified in Internal Medicine, Cardiovascular Disease and Advanced Heart Failure and Transplant Cardiology, is Director of Heart Failure Treatment and Transplant at the Barnabas Health Heart Center at Newark Beth Israel Medical Center and has been involved with heart transplantation since 1987. Under his leadership, the Heart Failure Treatment and Transplant Program at Newark Beth Israel was ranked among the top 10 programs in the nation in volume for the past three years. More than 440 heart transplants, 31 lung transplants and over 150 left ventricular assist device implants have been performed at Newark Beth Israel Medical Center. The program's results rival those at nationally renowned centers, with a one-year heart transplant survival rate over the past few years in excess of 91 percent and a three-year survival rate in excess of 80 percent. He subsequently joined the faculty at Loyola University Medical Center as one of four attending transplant cardiologists. He joined Newark Beth Israel Medical Center in 1989 as Director of Cardiac Transplantation and Associate Clinical Professor of Medicine at the Mount Sinai School of Medicine.

Dr. Zucker served as a Director of the original New Jersey Affiliate of the American Heart Association and is a founding member of the new Heritage Affiliate of the American Heart Association, for which he served as a member of the Board of Directors from 1998 to 2000. In 2004, Dr. Zucker was voted President/Governor of the New Jersey Chapter of the American College of Cardiology. In addition, he has served as a member of the Board of Directors of the New Jersey Organ and Tissue Sharing Network for more than 15 years, served twice as the Thoracic Representative for the Mid-Atlantic states to the United Network for Organ Sharing, and presently serves as the representative from the American College of Cardiology (ACC) Board of Governors to the ACC's Subcommittee on Heart Failure and Transplantation. Additionally, he is a member of the American Board of Internal Medicine Cardiovascular Board Advanced Heart Failure and Transplant Cardiology Exam Committee.

Dr. Zucker attended Northwestern University's School of Medicine where he remained for his residency in internal medicine followed by clinical and research fellowships in cardiology. In addition to practicing medicine, Dr. Zucker is a graduate of Loyola University Law School and is admitted to practice law in New Jersey, New York and Illinois.

As of January 2017, Dr. Zucker reported the following external relationships:

Funding for clinical trial expenses, paid to Newark Beth Israel Medical Center, from the following companies:

  • Alnylam Pharmaceuticals, for a study of small interfering RNA to treat amyloidosis.
  • Mesoblast, for a study of stem cells.
  • Pfizer, for a study of tafamidis in the treatment of transthyretin amyloid cardiomyopathy (ATTR-ACT Trial).
  • Prothena Corporation, for a study of drug designed to treat amyloid light-chain amyloidosis.
  • St. Jude, for a study of a left ventricular assist device.
  • Vericel Biosciences,for a stem cell trial.

Dr. Zucker serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American College of Cardiology, Councilor, New Jersey Chapter, without compensation.
  • NJ Sharing Network, serving as Chair, Advisory Board of the New Jersey Organ and Tissue Sharing Network, without compensation.